左氧氟沙星和莫西沙星治疗耐多药肺结核病的临床效果比较

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (33 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨左氧氟沙星和莫西沙星治疗耐多药肺结核病的临床效果。方法选取2016年1～9月在我院治疗的160 例耐多药肺结核病患者作为研究对象，按照随机数字表法将其分为对照组与实验组，每组各80 例。对照组患者采用左氧氟沙星联合卷曲霉素为主治疗，实验组患者应用莫西沙星联合卷曲霉素为主治疗。观察并比较两组患者的治疗效果、病灶吸收及痰菌变化情况。结果实验组患者的治疗总有效率为86.25%，高于对照组的61.25%，差异有统计学意义（P＜0.05）。实验组患者的病灶总吸收率为92.50%，高于对照组的78.75%，差异有统计学意义（P＜0.05）。治疗24 个月时，实验组患者的涂片阴性率为83.75%，痰结核菌阴性率为86.25%，均高于对照组的57.50%、58.75%，差异有统计学意义（P＜0.05）。结论耐多药肺结核病患者应用莫西沙星联合卷曲霉素治疗效果显著，可促进病灶吸收，增加痰菌转阴率，值得推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	党配英

关键词 ：莫西沙星, 左氧氟沙星, 耐多药肺结核病, 临床效果

Abstract：Objective To explore the clinical effect of Levofloxacin and Moxifloxacin in the treatment of multidrug-resistant pulmonary tuberculosis.Methods A total of 160 patients with multi-drug resistant pulmonary tuberculosis treated in our hospital from January to September 2016 were selected as research subjects, and they were divided into control group and experimental group according to the random number table method, with 80 cases in each group.The control group was mainly treated with Levofloxacin combined with Capreomycin, while the experimental group was mainly treated with Moxifloxacin combined with Capreomycin.The therapeutic effect, lesion absorption and sputum bacteria changes of the two groups were observed and compared.Results The total effective rate of treatment in the experimental group was 86.25%, which was higher than that in the control group accounting for 61.25%, and the difference was statistically significant (P＜0.05).The total absorption rate of lesions in the experimental group was 92.50%,which was higher than that in the control group accounting for 78.75%, and the difference was statistically significant(P＜0.05).The smear negative rate and sputum tuberculosis negative rate of the experimental group at 24 months of treatment were 83.75% and 86.25% respectively, which were significantly higher than those of the control group accounting for 57.50% and 58.75%, and the differences were statistically significant (P＜0.05).Conclusion Moxifloxacin combined with Capreomycin is effective in the treatment of multi-drug resistant pulmonary tuberculosis, which can promote lesion absorption and increase sputum negative rate.It is worthy of popularization and application.

Key words： Moxifloxacin Levofloxacin Multidrug-resistant pulmonary tuberculosis Clinical effect

引用本文:

党配英. 左氧氟沙星和莫西沙星治疗耐多药肺结核病的临床效果比较[J]. 中国当代医药, 2020, 27(3): 101-103转107.
DANG Pei-ying. Clinical effect comparison of Levofloxacin and Moxifloxacin in the treatment of multidrug-resistant pulmonary tuberculosis. 中国当代医药, 2020, 27(3): 101-103转107.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I3/101

[1]	张蕾蕾，金华，冯菊英，等.34 例未纳入全球基金耐多药结核病项目治疗的耐多药肺结核患者分析[J].中国全科医学，2017，20（17）：2135-2138.
[2]	李明霖，梁未雯，刚永桂，等.扶正抗痨方辅助治疗耐多药肺结核的痰菌阴转率及对免疫功能的影响[J].中国病原生物学杂志，2018，13（2）：192-195.
[3]	曹培明，严晓峰，沈明，等.复方新诺明联合二线药物治疗耐多药结核病的临床疗效分析[J].重庆医学，2018，47（2）：186-188.
[4]	应潜，黄文辉，陈小菁，等.282 例肺结核患者结核分枝杆菌耐药基线调查及耐多药结核病影响因素分析[J].现代预防医学，2018，45（19）：3597-3600.
[5]	许怡，张志，田岳飏，等.河北省五市结核分枝杆菌耐药情况及耐多药菌株对利奈唑胺的敏感性[J].中国感染控制杂志，2018，17（3）：191-195.
[6]	陈旋，张炜.美罗培南联合克拉维酸对耐多药和广泛耐药结核分枝杆菌的作用[J].中华结核和呼吸杂志，2018，41（1）：51-54.
[7]	王娅，李佺，杨澄清，等.含环丝氨酸方案治疗耐多药肺结核出现严重精神症状的临床分析[J].中国热带医学，2017，17（3）：260-262.
[8]	Tang P，Wang X，Shen X，et al.Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid[J].Exp Ther Med，2017，13（5）：2232-2238.
[9]	闫丽萍，吴哲渊，张祖荣，等.初治耐多药肺结核患者采用初治标准方案治疗的前瞻性临床研究[J].中国防痨杂志，2017，39（1）：33-38.
[10]	李杨，王飞，吴琍敏，等.环丝氨酸在耐多药结核病化学治疗中应用价值的探讨[J].中国防痨杂志，2018，40（2）：168-172.
[11]	武延琴，任斐，党丽云，等.西安市111 例耐多药肺结核患者的药物敏感试验结果[J].中国热带医学，2018，18（6）：563-567.
[12]	王建云，贾忠，魏宝楚，等.耐多药肺结核采用含阿米卡星或卷曲霉素化疗方案治疗的结果分析[J].中国防痨杂志，2017，39（7）：779-783.
[13]	何贵清，孙峰，苏菲菲，等.2013～2015年温州市耐多药肺结核患者队列标准化疗方案的治疗转归[J].中国防痨杂志，2018，40（2）：161-167.
[14]	Wu J，Wang S，Lu C，et al.Multiplecytokine responses in discriminating between Active tuberculosis and latenttuberculosis infection[J].Tuberculosis（Edinb），2017，11（102）：68-75.
[15]	吕桂兰.化疗配合莫西沙星和卷曲霉素治疗耐多药肺结核的价值研究[J].中国疗养医学，2019，28（2）：197-198.